Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Prelude Therapeutics IncPRLD · Entity 5561 | EVP and Chief of Business Oper | September 02, 2021 | September 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Prelude Therapeutics Inc
Report date September 02, 2021 · Filed September 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,750 |
Ending reported balance
After 2021-09-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-09-02 · Exercise / conversion · Acquired 17,000 · Balance 20,750 Row 2 · 2021-09-02 · Sale · Disposed 3,343 · Balance 17,407 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Row 3 · 2021-09-02 · Sale · Disposed 6,727 · Balance 10,680 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Row 4 · 2021-09-02 · Sale · Disposed 6,930 · Balance 3,750 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.85 · Expires 2030-09-01 | Direct | 207,796 |
Reported balance
After 2021-09-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-09-02 · Exercise / conversion · Disposed 17,000 · Balance 207,796 F5: The stock option vests as to 25% of the total shares monthly beginning on July 27, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F5: The stock option vests as to 25% of the total shares monthly beginning on July 27, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2021 Filed Sep 7, 2021 23:17 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $12.85 | $0.00 |
DisclosureSEC source: 0001209191-21-055072 · doc4.xml · derivative · entry 5 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,796 Underlying: Common Stock · 17,000 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares monthly beginning on July 27, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:17 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 6,930 | $42.50 | $294,506.98 |
DisclosureSEC source: 0001209191-21-055072 · doc4.xml · nonDerivative · entry 4 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:17 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 6,727 | $41.52 | $279,288.90 |
DisclosureSEC source: 0001209191-21-055072 · doc4.xml · nonDerivative · entry 3 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,680 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:17 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 3,343 | $40.29 | $134,696.82 |
DisclosureSEC source: 0001209191-21-055072 · doc4.xml · nonDerivative · entry 2 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,407 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:17 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 17,000 | $12.85 | $218,450.00 |
DisclosureSEC source: 0001209191-21-055072 · doc4.xml · nonDerivative · entry 1 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 22:11 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $31.23 | $0.00 |
DisclosureSEC source: 0001209191-21-047839 · doc4.xml · derivative · entry 1 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2031-07-19 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 22:24 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,295 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-029352 · doc4.xml · derivative · entry 3 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,323 Underlying: Common Stock · 3,295 shares Expires 2030-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 22:24 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 3,295 | $40.29 | $132,764.78 |
DisclosureSEC source: 0001209191-21-029352 · doc4.xml · nonDerivative · entry 2 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 22:24 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 3,295 | $1.89 | $6,227.55 |
DisclosureSEC source: 0001209191-21-029352 · doc4.xml · nonDerivative · entry 1 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 23:12 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 200 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-026874 · doc4.xml · derivative · entry 3 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,618 Underlying: Common Stock · 200 shares Expires 2030-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 23:12 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 200 | $40.00 | $8,000.00 |
DisclosureSEC source: 0001209191-21-026874 · doc4.xml · nonDerivative · entry 2 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 23:12 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantCommon Stock | 200 | $1.89 | $378.00 |
DisclosureSEC source: 0001209191-21-026874 · doc4.xml · nonDerivative · entry 1 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,950 Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:53 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 828 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-026293 · doc4.xml · derivative · entry 3 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,818 Underlying: Common Stock · 828 shares Expires 2030-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:53 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 828 | $40.08 | $33,188.39 |
DisclosureSEC source: 0001209191-21-026293 · doc4.xml · nonDerivative · entry 2 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:53 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantCommon Stock | 828 | $1.89 | $1,564.92 |
DisclosureSEC source: 0001209191-21-026293 · doc4.xml · nonDerivative · entry 1 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,578 Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 00:07 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 3,750 | $19.00 | $71,250.00 |
DisclosureSEC source: 0001209191-20-052400 · doc4.xml · nonDerivative · entry 1 Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.